| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2031 | 2018 |
| Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma GV Long, AM Menzies, AM Nagrial, LE Haydu, AL Hamilton, GJ Mann, ... Journal of Clinical Oncology 29 (10), 1239-1246, 2011 | 1279 | 2011 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709-717, 2017 | 1074 | 2017 |
| Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ... The Lancet Oncology 19 (5), 672-681, 2018 | 897 | 2018 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 812 | 2017 |
| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 659 | 2019 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 630 | 2016 |
| BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical cancer research 20 (7), 1965-1977, 2014 | 569 | 2014 |
| Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 550 | 2018 |
| Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma AM Menzies, LE Haydu, L Visintin, MS Carlino, JR Howle, JF Thompson, ... Clinical cancer research 18 (12), 3242-3249, 2012 | 541 | 2012 |
| PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L 1 clinical trials J Madore, RE Vilain, AM Menzies, H Kakavand, JS Wilmott, J Hyman, ... Pigment cell & melanoma research 28 (3), 245-253, 2015 | 438 | 2015 |
| Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 … EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ... The Lancet Oncology 20 (7), 948-960, 2019 | 435 | 2019 |
| Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma GV Long, C Fung, AM Menzies, GM Pupo, MS Carlino, J Hyman, ... Nature communications 5 (1), 5694, 2014 | 388 | 2014 |
| sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ... Nature 532 (7598), 250-254, 2016 | 363 | 2016 |
| CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti … J Edwards, JS Wilmott, J Madore, TN Gide, C Quek, A Tasker, A Ferguson, ... Clinical Cancer Research 24 (13), 3036-3045, 2018 | 358 | 2018 |
| Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma MH Pollack, A Betof, H Dearden, K Rapazzo, I Valentine, AS Brohl, ... Annals of Oncology 29 (1), 250-255, 2018 | 340 | 2018 |
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ... European journal of cancer 51 (18), 2792-2799, 2015 | 339 | 2015 |
| Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ... Journal of Clinical Oncology 37 (11), 867-875, 2019 | 326 | 2019 |
| Immune checkpoint inhibitors in challenging populations DB Johnson, RJ Sullivan, AM Menzies Cancer 123 (11), 1904-1911, 2017 | 324 | 2017 |
| Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma JH Lee, GV Long, S Boyd, S Lo, AM Menzies, V Tembe, A Guminski, ... Annals of Oncology 28 (5), 1130-1136, 2017 | 315 | 2017 |
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore Hospital在 sydney.edu.au 的电子邮件经过验证
